217 related articles for article (PubMed ID: 24299960)
1. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Ransom D; Wilson K; Fournier M; Simes RJ; Gebski V; Yip D; Tebbutt N; Karapetis CS; Ferry D; Gordon S; Price TJ
Ann Oncol; 2014 Jan; 25(1):117-21. PubMed ID: 24299960
[TBL] [Abstract][Full Text] [Related]
2. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M
Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220
[TBL] [Abstract][Full Text] [Related]
3. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
5. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U
Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
8. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Scheithauer W; Kornek GV; Schuell B; Ulrich-Pur H; Penz M; Raderer M; Lang F; Schneeweiss B; Lenauer A; Depisch D
Ann Oncol; 2001 May; 12(5):709-14. PubMed ID: 11432632
[TBL] [Abstract][Full Text] [Related]
9. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
[TBL] [Abstract][Full Text] [Related]
10. New developments in systemic chemotherapy in advanced colorectal cancer.
Cats A
Scand J Gastroenterol Suppl; 2003; (239):78-86. PubMed ID: 14743888
[TBL] [Abstract][Full Text] [Related]
11. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.
Rosati G; Rossi A; Germano D; Reggiardo G; Manzione L
Anticancer Res; 2003; 23(3C):2981-5. PubMed ID: 12926149
[TBL] [Abstract][Full Text] [Related]
12. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
Carnaghi C; Zucali P; Garassino I
Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
[TBL] [Abstract][Full Text] [Related]
13. Treatment of colorectal cancer metastasis: the role of chemotherapy.
Xiong HQ; Ajani JA
Cancer Metastasis Rev; 2004; 23(1-2):145-63. PubMed ID: 15000155
[TBL] [Abstract][Full Text] [Related]
14. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
Koopman M; Antonini NF; Douma J; Wals J; Honkoop AH; Erdkamp FL; de Jong RS; Rodenburg CJ; Vreugdenhil G; Akkermans-Vogelaar JM; Punt CJ
Ann Oncol; 2006 Oct; 17(10):1523-8. PubMed ID: 16873425
[TBL] [Abstract][Full Text] [Related]
15. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
16. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Montagnani F; Chiriatti A; Licitra S; Aliberti C; Fiorentini G
Clin Colorectal Cancer; 2010 Oct; 9(4):243-7. PubMed ID: 20920997
[TBL] [Abstract][Full Text] [Related]
17. New oxaliplatin-based combinations in the treatment of colorectal cancer.
Cassidy J; Hochster H
Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
[TBL] [Abstract][Full Text] [Related]
18. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
Feliu J; Castañón C; Salud A; Mel JR; Escudero P; Pelegrín A; López-Gómez L; Ruiz M; González E; Juárez F; Lizón J; Castro J; González-Barón M;
Br J Cancer; 2005 Nov; 93(11):1230-5. PubMed ID: 16265344
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Haller DG; Rothenberg ML; Wong AO; Koralewski PM; Miller WH; Bodoky G; Habboubi N; Garay C; Olivatto LO
J Clin Oncol; 2008 Oct; 26(28):4544-50. PubMed ID: 18824706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]